Why is Retatrutide called a triple agonist?

Because it stimulates three receptors simultaneously:

• 
  GLP-1
  
• 
  GIP
  
• 
  Glucagon
  

Most currently available therapies target only one or two of these pathways.

What are researchers studying Retatrutide for?

Research is currently focused on:

• 
  Obesity management
  
• 
  Appetite regulation
  
• 
  Weight reduction
  
• 
  Insulin sensitivity
  
• 
  Metabolic disease
  
• 
  Energy balance
  

Is Upret 30 approved by SAHPRA or the FDA?

No. Retatrutide remains investigational and has not yet received approval from either SAHPRA or the FDA for routine clinical use.

What makes Retatrutide different from GLP-1 therapies?

Traditional GLP-1 therapies act on one receptor.

Tirzepatide acts on two receptors (GLP-1 and GIP).

Retatrutide acts on three receptors:

• 
  GLP-1
  
• 
  GIP
  
• 
  Glucagon
  

This broader mechanism may contribute to enhanced metabolic effects.

What is the active ingredient in Upret 30?

The active ingredient is:

Retatrutide (LY3437943).

Is Retatrutide the same as Semaglutide?

No.

Semaglutide targets only GLP-1 receptors, whereas Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously.

Is Retatrutide the same as Tirzepatide?

No.

Tirzepatide is a dual agonist (GLP-1/GIP), while Retatrutide is a triple agonist (GLP-1/GIP/Glucagon).

Why is there so much interest in Retatrutide?

Early clinical studies have demonstrated substantial reductions in body weight, making it one of the most closely watched investigational therapies in metabolic medicine today.

Active Ingredient: Retatrutide 30mg

Class: Triple agonist peptide (GLP-1, GIP, and Glucagon receptor agonist)

Retatrutide is currently being investigated for weight management and metabolic health due to its effects on appetite regulation, glucose metabolism, and energy expenditure. It is not yet approved by major regulatory agencies for routine clinical use.

Administration Guidelines

• 
  Administer subcutaneously once weekly.
  
• 
  Inject on the same day each week.
  
• 
  Common injection sites include:
  
  
  Abdomen
  
  
  Front of the thigh
  
  
  Upper outer arm
  
  
  
• 
  Rotate injection sites regularly.
  
• 
  Can be administered with or without food.
  
• 
  If a dose is missed and remembered within 4 days, administer it as soon as possible. If more than 4 days have passed, skip the missed dose and resume the normal schedule.
  

Storage

• 
  Store refrigerated at 2–8°C.
  
• 
  Do not freeze.
  
• 
  Protect from direct sunlight.
  
• 
  Follow manufacturer instructions regarding shelf life after first use.

Suggested Dosage Guideline

• 
  Begin with 2mg once weekly for the first 4 weeks.
  
• 
  Increase to 4mg once weekly for the next 4 weeks if well tolerated.
  
• 
  Increase to 6mg once weekly for a further 4 weeks.
  
• 
  Thereafter, increase to 8mg once weekly if additional effect is required and side effects remain manageable.
  
• 
  Advanced users may progress to 10–12mg once weekly, depending on individual response and tolerance.

Frequently Asked Questions (FAQs)

What is UPRET 30?

UPRET 30 is a 30mg formulation of Retatrutide, a next-generation peptide designed to target three receptors involved in metabolic regulation:

• 
  GLP-1 receptors
  
• 
  GIP receptors
  
• 
  Glucagon receptors
  

This triple mechanism may provide enhanced appetite suppression and metabolic support.

How does Retatrutide work?

It works by:

• 
  Reducing appetite and cravings
  
• 
  Increasing feelings of fullness
  
• 
  Improving insulin sensitivity
  
• 
  Enhancing energy expenditure
  
• 
  Supporting fat metabolism
  

How long does it take to notice results?

Many individuals report reduced appetite within the first few weeks. Meaningful changes in body composition generally become more noticeable after 8–12 weeks, particularly once higher maintenance doses are reached.

What are the most common side effects?

Common side effects may include:

• 
  Nausea
  
• 
  Constipation
  
• 
  Diarrhoea
  
• 
  Vomiting
  
• 
  Reduced appetite
  
• 
  Indigestion
  
• 
  Fatigue
  

These effects are generally more pronounced during dose escalation.

Who should avoid using UPRET 30?

Individuals should consult a healthcare professional before use, especially if they:

• 
  Have a history of pancreatitis
  
• 
  Have severe gastrointestinal disease
  
• 
  Have a personal or family history of medullary thyroid carcinoma
  
• 
  Have Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2)
  
• 
  Are pregnant or breastfeeding
  

Can UPRET 30 be combined with other GLP-1 medications?

It is generally not recommended to combine Retatrutide with other GLP-1 receptor agonists or dual incretin therapies unless specifically directed by a qualified healthcare professional.

Do I need to follow a diet and exercise plan?

Yes. Optimal outcomes are achieved when combined with:

• 
  A calorie-controlled diet
  
• 
  Adequate protein intake
  
• 
  Regular resistance training
  
• 
  Cardiovascular exercise
  
• 
  Proper hydration and sleep habits
  

Can people with diabetes use UPRET 30?

Because Retatrutide affects glucose regulation, individuals with diabetes should only use it under medical supervision, particularly if taking insulin or other glucose-lowering medications.

Is UPRET 30 approved by SAHPRA?

At present, Retatrutide remains an investigational therapy and has not been approved by SAHPRA for routine therapeutic use. Product information distributed locally notes that it has not been evaluated by SAHPRA for quality, safety, or intended use.

Background Research

The Science Behind Retatrutide

Retatrutide (LY3437943) was developed by Eli Lilly as an investigational therapy for obesity and metabolic disorders.

Unlike traditional GLP-1 medications, Retatrutide stimulates three hormone receptors simultaneously:

GLP-1 Activation

Supports:

• 
  Appetite reduction
  
• 
  Slower gastric emptying
  
• 
  Improved satiety
  
• 
  Enhanced insulin secretion
  

GIP Activation

Supports:

• 
  Glucose regulation
  
• 
  Insulin sensitivity
  
• 
  Nutrient utilization
  
• 
  Metabolic flexibility
  

Glucagon Activation

Supports:

• 
  Increased energy expenditure
  
• 
  Fat oxidation
  
• 
  Improved metabolic efficiency
  

This unique combination may explain why Retatrutide has generated substantial interest among researchers investigating obesity therapies.